Glucagon-like peptide 1 (GLP-1): A potent gut hormone with a possible therapeutic perspective

Acta Diabetologica

Volumn 35, Issue 3, 1998, Pages 117-129

  Nauck, M A ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Gastric inhibitory polypeptide; Glucagon like peptide 1; Gut hormones; Incretin; New treatment modalities; Obesity; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; INSULIN;

DIABETES MELLITUS; FOOD INTAKE; INSULIN RESPONSE; INSULIN SYNTHESIS; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING;

ANIMALS; CEREBRAL VENTRICLES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEEDING BEHAVIOR; GASTRIC EMPTYING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; HUMANS; INSULIN; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PROINSULIN; PROTEIN PRECURSORS;

EID: 0031758346     PISSN: 09405429     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005920050116     Document Type: Review

References (166)

1. Creutzfeldt W (1979) The incretin concept today. Diabetologia 16: 75-85
2. Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46: 1954-1962
3. Ebert R, Creutzfeldt W (1982) Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats. Endocrinol 111: 1601-1606
4. Ebert R, Unger H, Creutzfeldt W (1983) Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 24: 449-454
5. Schmidt WE, Siegel EG, Creutzfeldt W (1985) Glucagon-like peptide 1 but not glucagon-like peptide 2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28: 704-707
6. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC (1983) Exon duplication and divergence in the human preproglucagon gene. Nature 304: 368-371
7. Lopez LC, Frazier ML, Su C-J, Kumar A, Saunders GF (1983) Mammalian pancreatic proglucagon contains three glucagon-related peptides. Proc Natl Acad Sci USA 80: 5485-5489
8. Ørskov C, Bersani M, Johnsen AH, Hojrup P, Holst JJ (1989) Complete sequences of glucagon-like peptide-1 from human and pig small intestine. J Biol Chem 264: 12826-12829
9. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43: 535-539
10. Holst JJ (1994) Glucagon like peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107: 1848-1855
11. Mojsov S, Weir GC, Habener JF (1987) Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79: 616-619
12. Ørskov C, Holst JJ, Seier-Poulsen S, Kirkegaard P (1987) Pancreatic and intestinal processing of proglucagon in man. Diabetologia 30: 874-881
13. Patzelt C, Schiltz E (1984) Conversion of proproglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like peptides. Proc Natl Acad Sci USA 81: 5007-5011
14. Ørskov C, Tang-Christensen M, Holst JJ, Larsen PJ (1996) Distribution of glucagon-like peptide-1 (GLP-1) and other proglucagon-derivedpeptides in the rat. Diabetes 45 [Suppl 1]: 150A (Abstract)
15. Rouillé Y, Martin S, Steiner DF (1995) Differential processing of proglucagon by the subtilisin-like prohormone convertase PC2 and PC3 to generate either glucagon or glucagon-like peptide. J Biol Chem 270: 26488-26496
16. Dhanvantari S, Seidah NG, Brubaker PL (1996) Role of prohormone convertases in the tissue-specific processing of proglucagon. Mol Endocrinol 10: 342-355
17. Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM (1985) Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J Histochem Cytochem 33: 1080-1086
18. Ørskov C (1992) Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711
19. Eissele R, Göke R, Willemer S, et al. (1992) Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest 22: 283-291
20. Ørskov C, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV, Holst JJ (1986) Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology 119: 1467-1475
21. Shima K, Hirota M, Ohboshi C, Sato M, Nishino T (1987) Release of glucagon-like peptide 1 immunoreactivity from the perfused rat pancreas. Acta Endocrinol Copenh 114: 531-536
22. Sasaki H, Manaka H, Yamantani K, Tominaga M (1993) GLP-1 secretion coupled with Na/glucose transporter from the isolated perfused canine ileum. Digestion 54: 365-367
23. Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 56: 117-126
24. Herrmann-Rinke C, Vöge A, Hess M, Göke B (1995) Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 147: 25-31
25. Rocca AS, Brubaker PL (1995) Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology 136: 5593-5599
26. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W (1993) Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76: 912-917
27. Nauck MA, Siemsglüß J, Ørskov C, Holst JJ (1996) Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections. Z Gastroenterol 34: 159-166
28. Schirra J, Katschinski M, Weidmann C, et al. (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97: 92-103
29. Nauck MA, Holst JJ, Willms B, Schmiegel W (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105: 187-195
30. Hoyt EC, Lund PK, Winesett DE, et al. (1996) Effects of fasting, refeeding, and intraluminal triglyceride on proglucagon expression in jejunum and ileum. Diabetes 45: 434-439
31. Reimer RA, McBurney MI (1996) Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology 137: 3948-3956
32. Dumoulin V, Dakka T, Plaisancie P, Chayvialle JA, Cuber JC (1995) Regulation of glucagon-like peptide-1-(7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology 136: 5182-5188
33. Roberge JN, Brubaker PL (1993) Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 133: 233-240
34. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307
35. Fieseler P, Bridenbaugh S, Nustede R, et al. (1995) Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-1 but not by CCK-8. Am J Physiol 268: E949-E955
36. Balks HJ, Holst JJ, von zur Mühlen A, Brabant G (1997) Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. J Clin Endocrinol Metab 82: 786-790
37. Ranganath LR, Beety LM, Morgan LM, Wright JW, Howland R, Marks V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 38: 916-919
38. Turton MD, O'Shea D, Gunn I, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379: 69-72
39. Flint A, Raben A, Astrup A, Holst JJ (1998) Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101: 515-520
40. Ørskov C, Holst JJ (1987) Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47: 165-174
41. Mentlein R, Gallwitz B, Schmidt WE (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835
42. Deacon CF, Johnsen AH, Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957
43. 2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44: 1126-1131
44. Kieffer TJ, McIntosh CH, Pederson RA (1995) Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136: 3585-3596
45. Grandt D, Sieburg B, Sievert J, Schimiczek M, Becker U, Holtmann D (1994) Is GLP-1 (9-36)amide an endogenous antagonist at GLP-1 receptors? Digestion 55: 302 (Abstract)
46. Pridal L, Ingwersen SH, Larsen FS, Holst JJ, Adelhorst K, Kirk O (1995) Comparison of sandwich enzyme-linked immunoadsorbent assay and radioimmunoassay for determination of exogenous glucagon-like peptide-1(7-3 6)amide in plasma. J Pharm Biomed Anal 13: 841-850
47. Miholic J, Ørskov C, Holst JJ, Kotzerke J, Meyer HJ (1991) Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy. Dig Dis Sci 36: 1361-1370
48. Miholic J, Ørskov C, Holst JJ, Kotzerke J, Pichlmayr R (1993) Postprandial release of glucagon-like peptide-1, pancreatic glucagon, and insulin after esophageal resection. Digestion 54: 73-78
49. Thorens B (1982) Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 89: 8641-8465
50. Thorens B, Porret A, Buhler L, Deng SP, Morel P, Widmann C (1983) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682
51. Moens K, Heimberg H, Flamez D, et al. (1996) Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45: 257-261
52. Kofod H, Kirk O, Adelhorst K (1996) Beta-cell receptors for glucagon/GLP-1? Properties of exendin(9-39) in mouse islets. Acta Physiol Scand 157: 347
53. Bullock BP, Heller RS, Habener JF (1996) Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 137: 2968-2978
54. Campos RV, Lee YC, Drucker DJ (1994) Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 134: 2156-2164
55. Wei Y, Mojsov S (1995) Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 358: 219-224
56. Wei Y, Mojsov S (1996) Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand 157: 355-357
57. Scrocchi LA, Brown TJ, MaClusky N, et al. (1996) Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2: 1254-1258
58. Göke R, Trautmann ME, Haus E, et al. (1989) Signal transmis-sion after GLP-1(7-36) amide binding in RINm5F cells. Am J Physiol 257:G397-G401
59. 2+ channel activity. Endocrinology 133: 1685-1692
60. 2+ current but not K+ATP current in intact mouse pancreatic B-cells. Biochem Biophys Res Commun 207: 33-39
61. Holz GG, Kuhtreiber WM, Habener JF (1993) Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature 361: 362-365
62. Holz GG, Leech CA, Habener JF (1995) Activation of a cAMP-regulated Ca(2+)-signaling pathway in pancreatic beta-cells by the insulinotropic hormone glucagon-like peptide-1. J Biol Chem 270: 17749-17757
63. Kato M, Ma HT, Tatemoto K (1996) GLP-1 depolarizes the rat pancreatic beta cell in a Na(+)-dependent manner. Regul Pept 62: 23-27
64. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet 2: 1300-1304
65. Kolligs F, Fehmann HC, Göke R, Göke B (1995) Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes 44: 16-19
66. Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA, Bloom SR (1995) Glucagon-like peptide-1 is a physiological incretin in rat. J Clin Invest 95: 417-421
67. Ørskov C, Holst JJ, Nielsen OV (1988) Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009-2013
68. Kawai K, Suzuki S, Ohashi S, et al. (1989) Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. Endocrinology 124: 1768-1773
69. Fehmann HC, Gherzi R, Göke B (1995) Regulation of islet hormone gene expression by incretin hormones. Exp Clin Endocrinol Diabetes 103 [Suppl 2]: 56-65
70. Göke R, Wagner B, Fehmann HC, Göke B (1993) Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med Berl 193: 97-103
71. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W (1995) Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32: 13-16
72. Hargrove DM, Nardone NA, Persson LM, Parker JC, Stevenson RW (1995) Glucose-dependent action of glucagon-like peptide-1 (7-37) in vivo during short- or long-term administration. Metabolism 44: 1231-1237
73. Gromada J, Rorsman P, Dissing S, Wulff BS (1995) Stimulation of cloned human glucagon-like peptide 1 receptor expressed in HEK 293 cells induces cAMP-dependent activation of calcium-induced calcium release. FEBS Lett 373: 182-186
74. Gromada J, Dissing S, Bokvist K, et al. (1995) Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting βTC3-cells by enhancement of intracellular calcium mobilization. Diabetes 44: 767-774
75. Gromada J, Ding WG, Barg S, Renstrom E, Rorsman P (1997) Multisite regulation of insulin secretion by cAMP-increasing agonists: evidence that glucagon-like peptide 1 and glucagon act via distinct receptors. Pflugers Arch 434: 515-524
76. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P (1998) Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 47: 57-65
77. Gromada J, Holst JJ, Rorsman P (1998) Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflügers Arch - Eur J Physiol 435: 583-594
78. 2+ channel of rat pancreatic β-cell in a cAMP-dependent manner. Diabetes 46: 1755-1760
79. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (noninsulin-dependent) diabetic patients. Diabetologia 36: 741-744
80. Weber I, Bach-Esser AK, Bach I, et al. (1995) Prolonged normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in Type 2-diabetic patients. Diabetologia 38 [Suppl 1]: A171 (Abstract)
81. Hargrove DM, Nardone NA, Persson LM, et al. (1996) Comparison of the glucose dependency of glucagon-like peptide-1 (7-37) and glyburide in vitro and in vivo. Metabolism 45: 404-409
82. Toft-Nielsen M, Hvidberg A, Hilsted J, Dige Petersen H, Holst JJ (1996) No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects. Diabet Med 13: 544-548
83. Komatsu R, Matsuyama T, Namba M, et al. (1989) Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38: 902-905
84. Heller RS, Aponte GW (1995) Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7-3 6) amide. Am J Physiol 269: G852-G860
85. Creutzfeldt WO, Kleine N, Willms B, Ørskov C, Holst JJ, Nauck MA (1996) Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-3 6) amide in type I diabetic patients. Diabetes Care 19: 580-586
86. Ritzel R, Ørskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725
87. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ (1993) Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38: 665-673
88. Wettergren A, Petersen H, Orskov C, Christiansen J, Sheikh SP, Holst JJ (1994) Glucagon-like Peptide-1 7-36 amide and peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 29: 501-505
89. Willms B, Werner J, Holst JJ, Ørskov C, Creutzfeldt W, Nauck MA (1996) Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81: 327-332
90. Nauck MA, Niedereichholz U, Ettler R, et al. (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273: E981-E988
91. Schjoldager BT, MortensenPE, Christiansen J, Ørskov C, Holst JJ (1989) GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 34: 703-708
92. 2: a physiological inhibitor of gastric acid secretion in man. J Endocrinol 126: 169-173
93. Ruiz Grande C, Alarcon C, Merida E, Valverde I (1992) Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 13: 13-16
94. Valverde I, Morales M, Clemente F, et al. (1994) Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349: 313-316
95. Valverde I, Villanueva Penacarrillo ML (1996) In vitro insulinomimetic effects of GLP-1 in liver, muscle and fat. Acta Physiol Scand 157: 359-360
96. Villanueva Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, Valverde I (1994) Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37: 1163-1166
97. Egan JM, Montrose Rafizadeh C, Wang Y, Bernier M, Roth J (1994) Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135: 2070-2075
98. Miki H, Namba M, Nishimura T, et al. (1996) Glucagon-like peptide-1(7-36)amide enhances insulin-stimulated glucose uptake and decreases intracellular cAMP content in isolated rat adipocytes. Biochim Biophys Acta 1312: 132-136
99. Fürnsinn C, Ebner K, Waldhäusl W (1995) Failure of GLP-1 (7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38: 864-867
100. Nakagawa Y, Kawai K, Suzuki H, Ohasi S, Yamashita K (1997) Glucagon-like peptide-1 (7-36) amide and glycogen synthesis in the liver. Diabetologia 40: 1241-1242
101. Merida E, Delgado E, Molina LM, Villanueva Penacarrillo ML, Valverde I (1993) Presence of glucagon and glucagon-like peptide-1-(7-36)amide receptors in solubilized membranes of human adipose tissue. J Clin Endocrinol Metab 77: 1654-1657
102. Valverde E, Diaz de Rada O, Burrell MA, Rovira J, Sesma P (1993) Immunocytochemical and ultrastructural characterization of endocrine cells and nerves in the intestine of Rana temporaria. Tissue Cell 25: 505-516
103. Valverde I, Merida E, Delgado E, Trapote MA, Villanueva Penacarrillo ML (1993) Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 132: 75-79
104. Villanueva Penacarrillo ML, Delgado E, Trapote MA, et al. (1995) Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146: 183-189
105. Delgado E, Luque MA, Alcantara A, et al. (1995) Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16: 225-229
106. Toft-Nielsen M-B, Madsbad S, Holst JJ (1996) The effect of glucagon-like peptide I (GLP-1) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes 45: 552-556
107. Gutniak MK, Holst JJ, Ørskov C, Åhren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)-amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322
108. Ørskov L, Holst J, Moller J, et al. (1996) GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia 39: 552-556
109. Ähren B, Larsson H, Holst JJ (1997) Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82: 473-478
110. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose Rafizadeh C (1995) Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 136: 4910-4917
111. Thorens B, Dériaz N, Bosco D, et al. (1996) Protein kinase A-dependent phosphorylation of GLUT 2 in pancreatic β-cells. J Biol Chem 271: 8075-8081
112. Beak SA, Small CJ, Ilovaiskaia I, et al. (1996) Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells. Endocrinology 137: 4130-4138
113. Beak SA, Heath MM, Small CJ, et al. (1998) Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line. J Clin Invest 101: 1334-1341
114. Lamari Y, Boissard C, Moukhtar MS, Jullienne A, Rosselin G, Garel JM (1996) Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett 393: 248-252
115. Shimizu I, Hirota M, Ohboshi C, Shima K (1987) Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121: 1076-1082
116. Kauth T, Metz J (1987) Immunohistochemical localization of glucagon-like peptide 1. Use of poly- and monoclonal antibodies. Histochemistry 86: 509-515
117. Kanse SM, Kreymann B, Ghatei MA, Bloom SR (1988) Identification and characterization of glucagon-like peptide-1 7-36 amide-binding sites in the rat brain and lung. FEBS Lett 241: 209-212
118. Tang Christensen M, Larsen PJ, Göke R, et al. (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271:R848-R856
119. Navarro M, Rodriquez de Fonseca F, Alvarez E, et al. (1996) Colocalization of glucagon-like peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for food and water intake. J Neurochem 67: 1982-1991
120. Shughrue PJ, Lane MV, Merchenthaler I (1996) Glucagon-like peptide-1 receptor (GLP1-R) mRNA in the rat hypothalamus. Endocrinology 137: 5159-5162
121. Göke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995) Identification of specific binding sites for glucagon-like peptide-1 on the posterior lobe of the rat pituitary. Neuroendocrinology 62: 130-134
122. O'Shea D, Gunn I, Chen X, Bloom S, Herbert J (1996) A role for central glucagon-like peptide-1 in temperature regulation. Neuroreport 7: 830-832
123. Ørskov C, Poulsen SS, Møller M, Holst JJ (1996) Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45: 832-835
124. Gutzwiller JP, Göke B, Drewe J, et al. (1997) Glucagon-like peptide-1 is a physiologic regulator of food intake in humans. Gastroenterol 112 [Suppl]:A1153 (Abstract)
125. Tseng C-C, Kieffer TJ, Jarboe LA, Usdin TB, Wolfe MM (1996) Postprandial stimulation of insulin release by glucose-dependent insulinotropic peptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J Clin Invest 98: 2440-2445
126. Nauck MA, Homberger E, Siegel EG, et al. (1986) Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498
127. Tillil H, Shapiro ET, Miller A, et al. (1988) Dose-dependent effects of oral and intravenous glucose on insulin secretion and clearance in normal humans. Am J Physiol 254: E349-E357
128. Creutzfeldt W, Nauck M (1992) Gut hormones and diabetes mellitus. Diabetes Metab Rev 8: 149-177
129. Wettergren A, Maina P, Boesby S, Holst JJ (1997) Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man. Scand J Gastroenterol 32: 552-555
130. Wettergren A, Wojdemann M, Meisner S, Stadil F, Holst JJ (1997) The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40: 597-601
131. Layer P, Holst JJ, Grandt D, Goebell H (1995) Heal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 40: 1074-1082
132. Schirra J, Sturm K, Leicht P, Arnold R, Göke B, Katschinski M (1997) Exendin(9-39)amide is a potent specific antagonist of glucagon-like peptide-1(7-36)amide in humans. Gastroenterol 112 [Suppl]:A186 (Abstract)
133. DeFronzo RA (1988) The triumvirate: β-cell, muscle and liver. A collusion responsible for NIDDM. Diabetes 37: 667-687
134. Gerich JE (1989) Abnormal glucagon secretion in type 2 (noninsulin-dependent) diabetes mellitus: causes and consequences. In: Creutzfeldt W, Lefèbvre P (eds) Diabetes mellitus: pathophysiology and therapy. Springer, Berlin Heidelberg, pp 127-133
135. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA (1995) Mechanism of accelerated gastric emptying and hyperglycemia in patients with type 2 diabetes mellitus. Gastroenterol 109: 755-765
136. Rahier J, Goebbels RM, Henquin JC (1983) Cellular composition of the human diabetic pancreas. Diabetologia 24: 366-371
137. Rahier JRD, Ibrahim M, Channaoui K (1989) Islet cell populations in obese subjects and type 2 (non-insulin-dependent) diabetic patients. Diabetologia 32 [Suppl 1]: 532A (Abstract)
138. Ohlson L-O, Larsson B, Svärdsudd K, et al. (1985) The influence of body fat distribution on the incidence of diabetes mellitus. Diabetes 34: 1055-1058
139. Suzuki S, Kawai K, Ohashi S, Mukai H, Murayama Y, Yamashita K (1990) Reduced insulinotropic effects of glucagonlike peptide 1-(7-36)-amide and gastric inhibitory polypeptide in isolated perfused diabetic rat pancreas. Diabetes 39: 1320-1325
140. Elahi D, McAloon Dyke M, Fukagawa NK, et al. (1994) The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects. Regul Pept 51: 63-74
141. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF (1992) Insulinotropic action of glucagon-like peptide 1 (7-37) in diabetic and non-diabetic subjects. Diabetes Care 15: 270-276
142. Nauck MA, Holst JJ, Willms B (1997) Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 29: 411-416
143. Rachman J, Gribble FM, Levy JC, Turner RC (1997) Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 40: 205-211
144. Larsen J, Jallad N, Damsbo P (1996) One-week continuous infusion of GLP-1 (7-37) improves glycaemic control in NIDDM. Diabetes 45 [Suppl 2]: 233A (Abstract)
145. Larsen J, Damsbo P (1997) GLP-1 must be present continuously in order to obtain a good glycaemic control in NIDDM. Diabetes 46 [Suppl I]: 186A (Abstract)
146. Juntti-Berggren L, Pigon J, Karpe F, et al. (1996) The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dislipoproteinemia in NIDDM patients. Diabetes Care 19: 1200-1206
147. Todd JJ, Wilding JPH, Edwards CMB, Khan FA, Ghatei MA, Bloom SR (1997) Glucagon-like peptide 1: a trial of treatment of non-insulin dependent diabetes mellitus. Eur J Clin Invest 27: 533-536
148. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC (1996) Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45: 1524-1530
149. Sauerwald A, Nauck MA, Holst JJ, Schmiegel WH (1997) Influence of glucagon-like peptide 1 on fasting hyperglycaemia in NIDDM patients treated with insulin (sulfonylurea failure). Diabetologia 40 [Suppl 1]:A46 (Abstract)
150. Dupré J, Behme MT, Hramiak M, et al. (1995) Glucagon-like peptide 1 reduces postprandial glycemic excursions in IDDM. Diabetes 44: 626-630
151. Gutniak MK, Linde B, Holst JJ, Efendic S (1994) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17: 1039-1044
152. Nauck MA, Wollschläger D, Werner J, et al. (1996) Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39: 1546-1553
153. Johnson OFL, Cleland JL, Lee HJ, et al. (1996) A month-long effect from a single injection of microencapsulated human growth hormone. Nature Med 2: 795-799
154. Mathiowitz E, Jacob JS, Jong YS, et al. (1997) Biologically erodable microspheres as potential oral drug delivery systems. Nature 386: 410-414
155. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobson O, Holst JJ (1998) Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia 41: 271-278
156. Deacon CF, Highes TE, Holst JJ (1998) Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. Diabetes 47: 764-769
157. Wrighton NC, Farrell FX, Chang R, et al. (1996) Small peptide as potent mimetics of the protein hormone erythropoietin. Science 273: 458-463
158. Gutniak MK, Larsson H, Heiber SJ, Juneskans OT, Holst JJ, Ähren B (1996) Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet. Diabetes Care 19: 843-848
159. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W (1995) Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 30: 892-896
160. Göke B, Fuder H, Wieckhorst G, et al. (1995) Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 56: 493-501
161. Ranganath L, Norris F, Morgan L, Wright J, Marks V (1998) Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its antihyperglycaemic effect. Diabet Med 15: 120-124
162. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA (1998) Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic
163. Siegel EG, Schulze A, Schmidt WE, Creutzfeldt W (1992) Comparison of the effect of GIP and GLP-1 (7-36 amide) on insulin release from rat pancreatic islets. Eur J Clin Invest 22: 154-157
164. Weir GC, Mojsov S, Hendrick GK, Habener JF (1989) Glucagon like peptide I (7-37) actions on endocrine pancreas. Diabetes 38: 338-342
165. Nauck MA (1996) Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabet Med 13 [Suppl]: S39-S43
166. Nauck MA, Holst JJ, Willms B, Schmiegel W (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105: 187-195